Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Pioglitazone (02303124), PMS-Pioglitazone (02303132), PMS-Pioglitazone (02303140). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Pioglitazone HCL
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Jamp-Pioglitazone · DIN 02397307 · 15 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Jamp-Pioglitazone · DIN 02397307
Manufacturer: Jamp Pharma Corporation; listing date 2013-04-30
Health Canada: Marketed since 2025-03-04 · brand JAMP PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Pioglitazone: Formulary list price $1.57 per unit (the source does not state the unit; exact figure $1.5716). What the ministry pays, not the patient.
Ministry pays: $1.5716 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02397307)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02397307).
DIN 02397307: Jamp-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002019; group id 751; item number 1840; lccId None; manufacturer id JPC
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.5716; ministry $1.5716
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02397307
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88227
Interchangeable products
Accel Pioglitazone · DIN 02303442 · $1.3800
Actos · DIN 02242572 · $1.5716
Apo-Pioglitazone · DIN 02302942 · $1.5716
Auro-Pioglitazone · DIN 02384906 · $1.5716
Mint-Pioglitazone · DIN 02326477 · $1.5716
Pioglitazone Hydrochloride Tablets · DIN 02391600 · $1.5716
Sandoz Pioglitazone · DIN 02297906 · $1.5716
Teva-Pioglitazone · DIN 02274914 · $1.5716
Teva-Pioglitazone · DIN 02302861 · $1.5716
Shortage status: resolved shortage (ended June 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397307
Shortage record checked October 6, 2026
Mint-Pioglitazone · DIN 02326477 · 15 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Mint-Pioglitazone · DIN 02326477
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2009-11-19
Health Canada: Marketed since 2022-03-03 · brand MINT-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Pioglitazone: Formulary list price $1.57 per unit (the source does not state the unit; exact figure $1.5716). What the ministry pays, not the patient.
Ministry pays: $1.5716 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02326477)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02326477).
DIN 02326477: Mint-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002019; group id 751; item number 1840; lccId None; manufacturer id MIN
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.5716; ministry $1.5716
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02326477
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81184
Interchangeable products
Accel Pioglitazone · DIN 02303442 · $1.3800
Actos · DIN 02242572 · $1.5716
Apo-Pioglitazone · DIN 02302942 · $1.5716
Auro-Pioglitazone · DIN 02384906 · $1.5716
Jamp-Pioglitazone · DIN 02397307 · $1.5716
Pioglitazone Hydrochloride Tablets · DIN 02391600 · $1.5716
Sandoz Pioglitazone · DIN 02297906 · $1.5716
Teva-Pioglitazone · DIN 02274914 · $1.5716
Teva-Pioglitazone · DIN 02302861 · $1.5716
Shortage status: resolved shortage (ended March 3, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02326477
Shortage record checked October 6, 2026
Teva-Pioglitazone · DIN 02302861 · 15 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Teva-Pioglitazone · DIN 02302861
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Marketed since 2025-12-12 · brand TEVA-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Pioglitazone: Formulary list price $1.57 per unit (the source does not state the unit; exact figure $1.5716). What the ministry pays, not the patient.
Ministry pays: $1.5716 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302861)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02302861).
DIN 02302861: Teva-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002019; group id 751; item number 1840; lccId None; manufacturer id TEV
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.5716; ministry $1.5716
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302861
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78818
Interchangeable products
Accel Pioglitazone · DIN 02303442 · $1.3800
Actos · DIN 02242572 · $1.5716
Apo-Pioglitazone · DIN 02302942 · $1.5716
Auro-Pioglitazone · DIN 02384906 · $1.5716
Jamp-Pioglitazone · DIN 02397307 · $1.5716
Mint-Pioglitazone · DIN 02326477 · $1.5716
Pioglitazone Hydrochloride Tablets · DIN 02391600 · $1.5716
Sandoz Pioglitazone · DIN 02297906 · $1.5716
Teva-Pioglitazone · DIN 02274914 · $1.5716
Shortage status: resolved shortage (ended January 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302861
Shortage record checked October 6, 2026
Jamp-Pioglitazone · DIN 02365529 · 30 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Jamp-Pioglitazone · DIN 02365529
Manufacturer: Jamp Pharma Corporation; listing date 2011-12-15
Health Canada: Marketed since 2025-03-04 · brand JAMP PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Pioglitazone: Formulary list price $2.20 per unit (the source does not state the unit; exact figure $2.2017). What the ministry pays, not the patient.
Ministry pays: $2.2017 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02365529)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02365529).
DIN 02365529: Jamp-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002020; group id 751; item number 1841; lccId None; manufacturer id JPC
Source form: Tab; strength: 30mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $2.2017; ministry $2.2017
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02365529
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85042
Interchangeable products
Accel Pioglitazone · DIN 02303450 · $1.9600
Actos · DIN 02242573 · $2.2017
Apo-Pioglitazone · DIN 02302950 · $2.2017
Auro-Pioglitazone · DIN 02384914 · $2.2017
Mint-Pioglitazone · DIN 02326485 · $2.2017
Pioglitazone Hydrochloride Tablets · DIN 02339587 · $2.2017
Sandoz Pioglitazone · DIN 02297914 · $2.2017
Teva-Pioglitazone · DIN 02274922 · $2.2017
Teva-Pioglitazone · DIN 02302888 · $2.2017
Shortage status: resolved shortage (ended June 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02365529
Shortage record checked October 6, 2026
Mint-Pioglitazone · DIN 02326485 · 30 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Mint-Pioglitazone · DIN 02326485
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2009-11-19
Health Canada: Marketed since 2022-03-03 · brand MINT-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Pioglitazone: Formulary list price $2.20 per unit (the source does not state the unit; exact figure $2.2017). What the ministry pays, not the patient.
Ministry pays: $2.2017 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02326485)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02326485).
DIN 02326485: Mint-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002020; group id 751; item number 1841; lccId None; manufacturer id MIN
Source form: Tab; strength: 30mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $2.2017; ministry $2.2017
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02326485
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81185
Interchangeable products
Accel Pioglitazone · DIN 02303450 · $1.9600
Actos · DIN 02242573 · $2.2017
Apo-Pioglitazone · DIN 02302950 · $2.2017
Auro-Pioglitazone · DIN 02384914 · $2.2017
Jamp-Pioglitazone · DIN 02365529 · $2.2017
Pioglitazone Hydrochloride Tablets · DIN 02339587 · $2.2017
Sandoz Pioglitazone · DIN 02297914 · $2.2017
Teva-Pioglitazone · DIN 02274922 · $2.2017
Teva-Pioglitazone · DIN 02302888 · $2.2017
Shortage status: resolved shortage (ended March 3, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02326485
Shortage record checked October 6, 2026
Teva-Pioglitazone · DIN 02302888 · 30 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Teva-Pioglitazone · DIN 02302888
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Marketed since 2025-12-12 · brand TEVA-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Pioglitazone: Formulary list price $2.20 per unit (the source does not state the unit; exact figure $2.2017). What the ministry pays, not the patient.
Ministry pays: $2.2017 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302888)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02302888).
DIN 02302888: Teva-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002020; group id 751; item number 1841; lccId None; manufacturer id TEV
Source form: Tab; strength: 30mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $2.2017; ministry $2.2017
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302888
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78819
Interchangeable products
Accel Pioglitazone · DIN 02303450 · $1.9600
Actos · DIN 02242573 · $2.2017
Apo-Pioglitazone · DIN 02302950 · $2.2017
Auro-Pioglitazone · DIN 02384914 · $2.2017
Jamp-Pioglitazone · DIN 02365529 · $2.2017
Mint-Pioglitazone · DIN 02326485 · $2.2017
Pioglitazone Hydrochloride Tablets · DIN 02339587 · $2.2017
Sandoz Pioglitazone · DIN 02297914 · $2.2017
Teva-Pioglitazone · DIN 02274922 · $2.2017
Shortage status: resolved shortage (ended November 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302888
Shortage record checked October 6, 2026
Jamp-Pioglitazone · DIN 02365537 · 45 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Jamp-Pioglitazone · DIN 02365537
Manufacturer: Jamp Pharma Corporation; listing date 2011-12-15
Health Canada: Marketed since 2025-03-04 · brand JAMP PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 45 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Pioglitazone: Formulary list price $3.31 per unit (the source does not state the unit; exact figure $3.3105). What the ministry pays, not the patient.
Ministry pays: $3.3105 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02365537)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02365537).
DIN 02365537: Jamp-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002021; group id 751; item number 1842; lccId None; manufacturer id JPC
Source form: Tab; strength: 45mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $3.3105; ministry $3.3105
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02365537
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85043
Interchangeable products
Accel Pioglitazone · DIN 02303469 · $2.9500
Actos · DIN 02242574 · $5.2710
Apo-Pioglitazone · DIN 02302977 · $3.3105
Auro-Pioglitazone · DIN 02384922 · $3.3105
Mint-Pioglitazone · DIN 02326493 · $3.3105
Pioglitazone Hydrochloride Tablets · DIN 02339595 · $3.3105
Sandoz Pioglitazone · DIN 02297922 · $3.3105
Teva-Pioglitazone · DIN 02274930 · $3.3105
Teva-Pioglitazone · DIN 02302896 · $3.3105
Shortage status: resolved shortage (ended June 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02365537
Shortage record checked October 6, 2026
Mint-Pioglitazone · DIN 02326493 · 45 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Mint-Pioglitazone · DIN 02326493
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2009-11-19
Health Canada: Marketed since 2022-03-03 · brand MINT-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 45 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Pioglitazone: Formulary list price $3.31 per unit (the source does not state the unit; exact figure $3.3105). What the ministry pays, not the patient.
Ministry pays: $3.3105 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02326493)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02326493).
DIN 02326493: Mint-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002021; group id 751; item number 1842; lccId None; manufacturer id MIN
Source form: Tab; strength: 45mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $3.3105; ministry $3.3105
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02326493
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81186
Interchangeable products
Accel Pioglitazone · DIN 02303469 · $2.9500
Actos · DIN 02242574 · $5.2710
Apo-Pioglitazone · DIN 02302977 · $3.3105
Auro-Pioglitazone · DIN 02384922 · $3.3105
Jamp-Pioglitazone · DIN 02365537 · $3.3105
Pioglitazone Hydrochloride Tablets · DIN 02339595 · $3.3105
Sandoz Pioglitazone · DIN 02297922 · $3.3105
Teva-Pioglitazone · DIN 02274930 · $3.3105
Teva-Pioglitazone · DIN 02302896 · $3.3105
Shortage status: resolved shortage (ended March 3, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02326493
Shortage record checked October 6, 2026
Teva-Pioglitazone · DIN 02302896 · 45 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Teva-Pioglitazone · DIN 02302896
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Marketed since 2025-12-12 · brand TEVA-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 45 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Pioglitazone: Formulary list price $3.31 per unit (the source does not state the unit; exact figure $3.3105). What the ministry pays, not the patient.
Ministry pays: $3.3105 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302896)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02302896).
DIN 02302896: Teva-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002021; group id 751; item number 1842; lccId None; manufacturer id TEV
Source form: Tab; strength: 45mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $3.3105; ministry $3.3105
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302896
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78820
Interchangeable products
Accel Pioglitazone · DIN 02303469 · $2.9500
Actos · DIN 02242574 · $5.2710
Apo-Pioglitazone · DIN 02302977 · $3.3105
Auro-Pioglitazone · DIN 02384922 · $3.3105
Jamp-Pioglitazone · DIN 02365537 · $3.3105
Mint-Pioglitazone · DIN 02326493 · $3.3105
Pioglitazone Hydrochloride Tablets · DIN 02339595 · $3.3105
Sandoz Pioglitazone · DIN 02297922 · $3.3105
Teva-Pioglitazone · DIN 02274930 · $3.3105
Shortage status: resolved shortage (ended January 14, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302896
Shortage record checked October 6, 2026
Apo-Pioglitazone · DIN 02302942 · 15 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since October 1, 2025 · checked October 5, 2026 · What does dormant mean? Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Apo-Pioglitazone · DIN 02302942
Manufacturer: Apotex Inc.; listing date 2008-01-15
Health Canada: Dormant since 2025-10-01 · brand APO-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Pioglitazone: Formulary list price $1.57 per unit (the source does not state the unit; exact figure $1.5716). What the ministry pays, not the patient.
Ministry pays: $1.5716 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302942)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02302942).
DIN 02302942: Apo-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002019; group id 751; item number 1840; lccId None; manufacturer id APX
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.5716; ministry $1.5716
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302942
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78824
Interchangeable products
Accel Pioglitazone · DIN 02303442 · $1.3800
Actos · DIN 02242572 · $1.5716
Auro-Pioglitazone · DIN 02384906 · $1.5716
Jamp-Pioglitazone · DIN 02397307 · $1.5716
Mint-Pioglitazone · DIN 02326477 · $1.5716
Pioglitazone Hydrochloride Tablets · DIN 02391600 · $1.5716
Sandoz Pioglitazone · DIN 02297906 · $1.5716
Teva-Pioglitazone · DIN 02274914 · $1.5716
Teva-Pioglitazone · DIN 02302861 · $1.5716
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302942
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since October 1, 2025 — choose a marketed DIN from the same-category list.
Pioglitazone Hydrochloride Tablets · DIN 02391600 · 15 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since September 18, 2026 · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Pioglitazone Hydrochloride Tablets · DIN 02391600
Manufacturer: Accord Healthcare Inc.; listing date 2012-12-21
Health Canada: Dormant since 2026-09-18 · brand ACH-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPioglitazone Hydrochloride Tablets: Formulary list price $1.57 per unit (the source does not state the unit; exact figure $1.5716). What the ministry pays, not the patient.
Ministry pays: $1.5716 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02391600)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02391600).
DIN 02391600: Pioglitazone Hydrochloride Tablets
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002019; group id 751; item number 1840; lccId None; manufacturer id ACH
Source form: Tab; strength: 15mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.5716; ministry $1.5716
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02391600
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87693
Interchangeable products
Accel Pioglitazone · DIN 02303442 · $1.3800
Actos · DIN 02242572 · $1.5716
Apo-Pioglitazone · DIN 02302942 · $1.5716
Auro-Pioglitazone · DIN 02384906 · $1.5716
Jamp-Pioglitazone · DIN 02397307 · $1.5716
Mint-Pioglitazone · DIN 02326477 · $1.5716
Sandoz Pioglitazone · DIN 02297906 · $1.5716
Teva-Pioglitazone · DIN 02274914 · $1.5716
Teva-Pioglitazone · DIN 02302861 · $1.5716
Shortage status: active shortage (reported October 27, 2023, last updated May 14, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02391600
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 18, 2026 — choose a marketed DIN from the same-category list.
Apo-Pioglitazone · DIN 02302950 · 30 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since July 9, 2025 · checked October 5, 2026
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Actos , Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For the treatment of type 2 diabetes in patients who require;
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal doses of metformin (2000 mg/day) OR
• Dual combination therapy of diabetes AND demonstrate inadequate glycemic control
(HbA1c of >7%) on maximal* doses of sulfonylurea and demonstrated intolerance /
contraindication to metformin OR
• Triple combination therapy of diabetes and who demonstrate inadequate glycemic
control on maximal** doses of metformin and a sulfonylurea AND only if the physician
has offered insulin as an alternative option first, and the patient has refused or is not
able to take insulin. Note: Both the physician and patient must be aware that
thiazolidinediones (TZDs), are not indicated for use in triple therapy.
***Those with one or more of the following contraindications/ precautions to therapy with
pioglitazone/rosiglitazone will not be considered
• Patients with type 1 diabetes
• Patients who will be using this as monotherapy
• Combination use with a nitrates
• Combination use with insulin
• Patients with any stage of heart failure (i.e. NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (i.e. post-menopausal women with
previously confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of an ischemic cardiovascular
event (myocardial infarction, unstable angina)
* Note: For the purpose of the EAP submission, maximal dose of sulfonylurea is
considered to be glyburide 10 mg/day, gliclazide 160mg/day OR Diamicron MR 60mg/day,
OR glimepiride (Amaryl ) 4 mg/day and aximal dose of metformin is considered to be 2000
mg/day.
Duration of Approval: 5 years
Renewals as well as requests for ongoing treatment in patients previously provided these
drugs by other means will be considered for those patients who have NOT developed a
contraindication/precautionary use*** in the intervening period AND have demonstrated a
recent HbA1c level ≤7% while on treatment
Duration of Approval: 5 years
34
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 34, record 15, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15 mg, 30 mg, 45 mg tablet
For dual combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control (HbA1c of >7%) on maximal doses of metformin (2000
mg/day); OR
b) Inadequate glycemic control, on maximal doses of sulfonylurea (glyburide 10mg/day,
gliclazide 160mg/day or gliclazide modified release (MR) 60 mg/day) or glimepiride 4
mg/day and demonstrated intolerance / contraindication to metformin
For triple combination therapy of type 2 diabetes, in patients with:
a) Inadequate glycemic control on maximal doses of metformin and a sulfonylurea AND
only if:
• physician has offered insulin as alternative option first, and patient has refused or
is not able to take insulin, AND both physician and patient are aware that
thiazolidinediones are not indicated for use in triple therapy.
Standard Approval Duration: 5 years
471
Pioglitazone
Brand(s): Generics
DOSAGE FORM/ STRENGTH: 15mg, 30 mg, 45 mg tablet
Renewals: EAP will renew pioglitazone only for patients who have achieved adequate
glycemic control (HbA1c of ≤ 7% while on therapy and who have no known
contraindications to pioglitazone.
Standard Approval Duration: 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 471, record 310, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Apo-Pioglitazone · DIN 02302950
Manufacturer: Apotex Inc.; listing date 2008-01-15
Health Canada: Dormant since 2025-07-09 · brand APO-PIOGLITAZONE · ATC A10BG03 PIOGLITAZONE · form Tablet · route Oral · ingredients PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Pioglitazone: Formulary list price $2.20 per unit (the source does not state the unit; exact figure $2.2017). What the ministry pays, not the patient.
Ministry pays: $2.2017 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302950)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02302950).
DIN 02302950: Apo-Pioglitazone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682002020; group id 751; item number 1841; lccId None; manufacturer id APX
Source form: Tab; strength: 30mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $2.2017; ministry $2.2017
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302950
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78825
Interchangeable products
Accel Pioglitazone · DIN 02303450 · $1.9600
Actos · DIN 02242573 · $2.2017
Auro-Pioglitazone · DIN 02384914 · $2.2017
Jamp-Pioglitazone · DIN 02365529 · $2.2017
Mint-Pioglitazone · DIN 02326485 · $2.2017
Pioglitazone Hydrochloride Tablets · DIN 02339587 · $2.2017
Sandoz Pioglitazone · DIN 02297914 · $2.2017
Teva-Pioglitazone · DIN 02274922 · $2.2017
Teva-Pioglitazone · DIN 02302888 · $2.2017
Shortage status: active shortage (reported June 25, 2024, last updated June 28, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302950
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 9, 2025 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (A10B, A10BG): coverage varies; not interchangeable
- Rosiglitazone (Avandia): not a benefit
- Canagliflozin (Invokana): general benefit
- Dapagliflozin (Forxiga): general benefit
- Dapagliflozin + metformin (Xigduo): general benefit
- Empagliflozin (Jardiance): general benefit
- Empagliflozin + metformin (Synjardy): general benefit
12 more in the class list below
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered
Matched class: 68:20:02 Oral Anti-Diabetic Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN
Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL
68:20:02 Oral Anti-Diabetic Agents
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg, 4mg, 8mg · Tab
· 8 products · General benefit · strengths: 100mg, 300mg · Tab
· 22 products · General benefit · strengths: 5mg, 10mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab
· 2 products · General benefit · strengths: 10mg, 25mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab
· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab
· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab
· 1 products · General benefit · strengths: 5mg · Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab
· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02
and 6 more
Full class listing
Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed)
Same formulary class, not same indication: class membership alone does not establish equivalent uses.